- Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
-
Yoneoka Y, Amano T, Takahashi A, Nishimura H, Deguchi M, Yamanaka H, Tanaka Y, Tsuji S, Murakami T
- KMID: 2561016
- Obstet Gynecol Sci.
- 2024 Nov;67(6):534-540.
- doi: 10.5468/ogs.24075
Objective There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the... -
- CITED
-
- Close
- SHARE
-
- Close
